vedolizumab   Click here for help

GtoPdb Ligand ID: 7437

Synonyms: Entyvio® | LDP-02 | LDP02 | MLN-0002 | MLN-002 | MLN002
Approved drug Immunopharmacology Ligand
vedolizumab is an approved drug (FDA and EMA (2014))
Compound class: Antibody
Comment: The peptide sequences for the heavy and light chains that form this antibody are annotated in its IMGT/mAb-DB record.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: vedolizumab

No information available.
Summary of Clinical Use Click here for help
Approved to treat adult patients with moderate to severe ulcerative colitis or moderate to severe Crohn‘s disease.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
This antibody binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1) [2]. α4β7 integrin directs leukocytes to mucosal and inflamed tissues. This integrin is only expressed on subsets of leukocytes, and this is found to restrict α4β7-induced inflammatory modulation to the gut [2]. Specifically, vedolizumab inhibits binding of α4β7 expressing leukocytes to mucosal addressin cell adhesion molecule 1 (MADCAM1, a lymphocyte homing receptor) and fibronectin, but not to vascular cell adhesion protein 1 (VCAM1) [2]. This has the effect of reducing bowel inflammation in patients with indicated conditions.
External links Click here for help